Breaking News Instant updates and real-time market news.

VSTM

Verastem

$1.31

0.055 (4.38%)

09:12
12/07/19
12/07
09:12
12/07/19
09:12

Verastem announces 62% response rate for duvelisib in T-cell lymphoma

Verastem announced the presentation of abstracts highlighting Copiktra data at the American Society of Hematology 2019 Annual Meeting. "Given the aggressive nature of peripheral T-cell lymphoma and the lack of effective therapeutic options for these patients, we are pleased to present data from the dose optimization phase of our PRIMO trial that demonstrated a 62% overall response rate, as assessed by independent central review, with a manageable safety profile consistent with previous clinical trials. The results of the trial also identified the optimal dosing regimen for future clinical study," said Brian Stuglik, Chief Executive Officer of Verastem Oncology. "The expansion phase of this registration-directed study is well underway. Upon completion, we plan to build upon our existing Fast Track Designation and Orphan Drug Designation and submit a regulatory package to the U.S. FDA with the goal of broadening the use of COPIKTRA to include treatment of PTCL." A total of 33 patients were treated in the dose optimization phase. Investigator-assessed ORRs were 35% in cohort 1 and 54% in cohort 2, with complete response rates of 25% and 31% in cohort 1 and cohort 2, respectively, the company said. Thirteen of 20 patients in cohort 1 and all patients in cohort 2 were able to complete one cycle of therapy. Seven patients in cohort 1 discontinued therapy early due to disease progression and/or toxicity. Another presentation at the meeting highlights new data from an investigator-sponsored Phase 1 study exploring duvelisib in combination with venetoclax in relapsed or refractory chronic lymphocytic leukemia/small lymphocytic lymphoma. Duvelisib plus venetoclax demonstrated promising clinical activity, a manageable tolerability profile, and a recommended Phase 2 dose of 400mg of venetoclax was determined for this regimen, according to Verastem.

  • 07

    Dec

VSTM Verastem
$1.31

0.055 (4.38%)

05/14/19
ROTH
05/14/19
NO CHANGE
Target $4
ROTH
Buy
Verastem price target lowered to $4 from $14 at Roth Capital
Roth Capital analyst Jotin Marango lowered his price target for Verastem to $4 from $14 as the company's Q1 update leaves him uncertain about the strategy and extra time that Verastem may need to eventually unlock that commercial value. The analyst reiterates a Buy rating on the shares.
06/20/19
BTIG
06/20/19
DOWNGRADE
BTIG
Neutral
Verastem downgraded to Neutral from Buy at BTIG
BTIG analyst Robert Hazlett downgraded Verastem to Neutral from Buy.
06/20/19
JONE
06/20/19
DOWNGRADE
JONE
Hold
Verastem downgraded to Hold from Buy at JonesTrading
06/20/19
JONE
06/20/19
NO CHANGE
JONE
Hold
JonesTrading downgrades Verastem as CEO marks third major management exit
As previously reported, JonesTrading analyst Matthew Cross downgraded Verastem to Hold from Buy after news that CEO Robert Forrester will be leaving the company. While this setback would have been "unexpected but manageable" by itself, the fact that this is the third major management departure gives him reason to pause and re-evaluate his view on the company, Cross tells investors. Despite Copiktra's initial difficulty, his talks with management leave him with reasons to be optimistic about a turnaround if the company can hit some of its goals in the next six months, added Cross.

TODAY'S FREE FLY STORIES

LIZI

Lizhi

$0.00

(0.00%)

10:26
01/17/20
01/17
10:26
01/17/20
10:26
Syndicate
Lizhi opens at $11.03, IPO priced at $11.00 per share »

Lizhi (LIZI) priced 4.1M…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Jan

10:25
01/17/20
01/17
10:25
01/17/20
10:25
Conference/Events
Wolfe Research tech strategist to hold an analyst/industry webcast »

Tech Strategist…

10:25
01/17/20
01/17
10:25
01/17/20
10:25
Conference/Events
UBS services analysts to hold an analyst/industry conference call »

Services Analyst Lasser,…

10:25
01/17/20
01/17
10:25
01/17/20
10:25
Conference/Events
Wolfe Research industrials analysts to hold an analyst/industry webcast »

Multi-Idndustry Analyst…

10:25
01/17/20
01/17
10:25
01/17/20
10:25
Conference/Events
JPMorgan U.S. telecom & semis analysts hold an analyst/industry conference call »

U.S. Telecom &…

10:25
01/17/20
01/17
10:25
01/17/20
10:25
Conference/Events
Cowen Washington policy strategist to hold an analyst/industry conference call »

Washington Policy…

MIDD

Middleby

$111.11

1.51 (1.38%)

, MCD

McDonald's

$212.00

1.14 (0.54%)

10:24
01/17/20
01/17
10:24
01/17/20
10:24
Recommendations
Middleby, McDonald's, Welbilt analyst commentary  »

Middleby equimpment may…

MIDD

Middleby

$111.11

1.51 (1.38%)

MCD

McDonald's

$212.00

1.14 (0.54%)

WBT

Welbilt

$15.39

-0.06 (-0.39%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 29

    Jan

CMS

CMS Energy

$65.31

-0.07 (-0.11%)

10:24
01/17/20
01/17
10:24
01/17/20
10:24
Downgrade
CMS Energy rating change  »

CMS Energy downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 30

    Jan

  • 12

    Mar

  • 13

    Mar

ES

Eversource

$87.64

-0.09 (-0.10%)

10:24
01/17/20
01/17
10:24
01/17/20
10:24
Downgrade
Eversource rating change  »

Eversource downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Jan

NEE

NextEra Energy

$252.14

-0.13 (-0.05%)

10:23
01/17/20
01/17
10:23
01/17/20
10:23
Downgrade
NextEra Energy rating change  »

NextEra Energy downgraded…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Jan

STT

State Street

$85.19

4.185 (5.17%)

10:22
01/17/20
01/17
10:22
01/17/20
10:22
Hot Stocks
State Street management 'confident in capital position' »

Comment from Q4 earnings…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Jan

  • 31

    Jan

  • 26

    Feb

10:20
01/17/20
01/17
10:20
01/17/20
10:20
Conference/Events
Wolfe Research energy analysts to hold an analyst/industry luncheon »

Energy Analysts…

GLD

SPDR Gold Shares

$146.63

0.33 (0.23%)

10:20
01/17/20
01/17
10:20
01/17/20
10:20
Options
Gold ETF call volume surges on March spread »

Gold ETF call volume…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

EOLS

Evolus

$11.43

0.25 (2.24%)

10:19
01/17/20
01/17
10:19
01/17/20
10:19
Recommendations
Evolus analyst commentary  »

Evolus shares offer…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

VEL

Velocity Financial

$0.00

(0.00%)

10:18
01/17/20
01/17
10:18
01/17/20
10:18
Syndicate
Breaking Syndicate news story on Velocity Financial »

Velocity Financial opens…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Jan

$NSD

NASDAQ Market Internals

$0.00

(0.00%)

10:17
01/17/20
01/17
10:17
01/17/20
10:17
Technical Analysis
NASDAQ market internals summary »

Volume is above average…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$NYE

NYSE Market Internals

$0.00

(0.00%)

10:16
01/17/20
01/17
10:16
01/17/20
10:16
Technical Analysis
NYSE market internals summary »

Volume is above average…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

10:15
01/17/20
01/17
10:15
01/17/20
10:15
General news
FX Action: The dollar »

FX Action: The dollar was…

10:15
01/17/20
01/17
10:15
01/17/20
10:15
General news
U.S. JOLTS reported job openings dropped -561k to 6,800k in November »

U.S. JOLTS reported job…

MDLA

Medallia

$31.67

-0.26 (-0.81%)

, GWB

Great Western

$34.30

-0.06 (-0.17%)

10:14
01/17/20
01/17
10:14
01/17/20
10:14
Initiation
Fly Intel: Top five analyst initiations »

Catch up on today's…

MDLA

Medallia

$31.67

-0.26 (-0.81%)

GWB

Great Western

$34.30

-0.06 (-0.17%)

TTEC

TTEC Holdings

$42.81

0.4 (0.94%)

BGNE

BeiGene

$169.94

2.055 (1.22%)

AMED

Amedisys

$181.47

0.28 (0.15%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Jan

  • 28

    Jan

  • 04

    Feb

  • 27

    Feb

MS

Morgan Stanley

$56.87

0.42 (0.74%)

, TWTR

Twitter

$34.39

0.2 (0.58%)

10:14
01/17/20
01/17
10:14
01/17/20
10:14
Downgrade
Fly Intel: Top five analyst downgrades »

Catch up on today's…

MS

Morgan Stanley

$56.87

0.42 (0.74%)

TWTR

Twitter

$34.39

0.2 (0.58%)

EBAY

eBay

$35.70

-0.21 (-0.58%)

CAKE

Cheesecake Factory

$39.21

-1.3 (-3.21%)

IBM

IBM

$137.21

-0.79 (-0.57%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Jan

  • 22

    Jan

  • 28

    Jan

  • 06

    Feb

  • 12

    Feb

WDC

Western Digital

$68.29

-0.33 (-0.48%)

, QCOM

Qualcomm

$93.76

1.99 (2.17%)

10:14
01/17/20
01/17
10:14
01/17/20
10:14
Upgrade
Fly Intel: Top five analyst upgrades »

Catch up on today's…

WDC

Western Digital

$68.29

-0.33 (-0.48%)

QCOM

Qualcomm

$93.76

1.99 (2.17%)

PINS

Pinterest

$23.36

0.4 (1.74%)

SNAP

Snap

$19.04

0.79 (4.33%)

YUM

Yum! Brands

$104.59

2.43 (2.38%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Jan

  • 30

    Jan

  • 04

    Feb

  • 05

    Feb

  • 06

    Feb

VEL

Velocity Financial

$0.00

(0.00%)

10:14
01/17/20
01/17
10:14
01/17/20
10:14
Syndicate
Velocity Financial indicated to open at $13.70, IPO priced at $13.00 »

Velocity Financial (VEL)…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Jan

SNV

Synovus

$39.86

0.24 (0.61%)

10:12
01/17/20
01/17
10:12
01/17/20
10:12
Conference/Events
Synovus management to meet with Stephens »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jan

  • 24

    Jan

  • 25

    Feb

  • 26

    Feb

PWFL

PowerFleet

$8.20

-0.04 (-0.49%)

10:10
01/17/20
01/17
10:10
01/17/20
10:10
Conference/Events
PowerFleet management to meet with Barrington »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jan

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.